Tovorafenib (Ojemda)
Mechanism of action
From the NCI Drug Dictionary: An orally available inhibitor of wild-type and certain mutant forms of A-Raf, B-Raf and C-Raf protein kinases, with potential antineoplastic activity. Upon administration, tovorafenib inhibits Raf-mediated signal transduction pathways, which may lead to an inhibition of tumor cell growth.
Diseases for which it is used
History of changes in FDA indication
- 2024-04-23: Granted accelerated approval to tovorafenib (Ojemda, Day One Biopharmaceuticals, Inc.) for patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. (Based on FIREFLY-1)
Also known as
- Code names: BIIB-024, DAY-101, MLN-2480, TAK-580
- Brand name: Ojemda